FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
|Slideshows|October 12, 2020
Medical Economics 2020 Burnout Survey Results: Physicians Face Unprecedented Crisis
Author(s)Patient Care Editorial Staff
Nearly two-thirds of physicians say the COVID-19 pandemic has made them feel more burned out.
Advertisement
Physician burnout was already at a crisis level. Has coronavirus disease 2019 (COVID-19) made it worse? For the second year our sister site,
Below you will find the complete and exclusive results of the survey, including physicians detailing how COVID-19 has affected them — in their own words.
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
Advertisement
Advertisement
Trending on Patient Care Online
1
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
2
FDA Grants Priority Review to Elinzanetant for VMS in HR+ Breast Cancer Patients on Endocrine Therapy
3
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
4
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
5